Immupharma Share Discussion Threads

[the imperialist] 30/8/2023 08:10

Final flush before an update?

[the imperialist] 21/8/2023 06:41

Chart still looks primed. I don't think today's RNS is the catalyst for the longer term trend change though.

[the imperialist] 11/8/2023 12:21

Looks like you guys are heading in the right direction. The chart would suggest you'll see 15p-ish in the not too distant.

[stockriser] 11/8/2023 11:16

My that's a long one !!!
------------------------------------------------

11/08/2023 12:04pm
UK Regulatory (RNS & others)

Immupharma (LSE:IMM)
Intraday Stock Chart

Friday 11 August 2023

Click Here for more Immupharma Charts.
TIDMIMM

RNS Number : 1084J

Immupharma PLC

11 August 2023

11 August 2023

ImmuPharma PLC

("ImmuPharma" or the "Company")

BOARD STRENGTHENED AHEAD OF NEXT PHASE OF COMPANY PROGRESSION

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides notification of changes to its Board of Directors.

It has been a pivotal 2023 for ImmuPharma, specifically within its P140 autoimmune platform.

Most recently in June, the Company announced that, after receiving comprehensive guidance from the Food & Drug Administration ("FDA") on the new Phase 2/3 adaptive clinical trial protocol for the lead programme for the treatment of patients with systemic lupus erythematosus ("SLE/Lupus"), it is moving forward with the study, together with its US partner Avion.

Positive progress on the P140 platform was also announced in May for a second high medical need disease, chronic idiopathic demyelinating polyneuropathy ("CIDP"). The Company received positive feedback from the FDA at a pre-IND meeting for a late-stage Phase 2/3 adaptive clinical program in patients, which is a further debilitating auto-immune condition within the Company's P140 platform.

In parallel with advancements in the late-stage clinical developments, the Company is also actively in discussions with a number of potential licensing partners for programmes across the Company's development portfolio.

In order to align with the new phase of progress, the Company recognised the need to add further skills and experience to the Board to ensure that we have the requisite Board composition for the next stage of evolution of the business.

We are therefore delighted to announce today the appointment of Dr Laurence Reilly as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.

He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Through his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice , Dr Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr Reilly previously served as a Clinician - Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

We are also extremely pleased to welcome Dr Sébastien Goudreau to the Board.

Dr Goudreau joined ImmuPharma in 2014 as research director and established the research laboratories of Ureka Pharma (now ImmuPharma Biotech, the Company's French subsidiary) in Bordeaux, being promoted in 2021 to Chief Executive Officer of ImmuPharma Biotech. Notably, working directly with Dr Tim Franklin (ImmuPharma COO), Dr Goudreau and his team are credited for the development of, among others, the Company's anti-infective programmes, BioAMB and BioCin.

Dr Goudreau has also been a key contributor to the progression of the P140 autoimmune platform including the PK study, successfully concluded in 2022, and supported the new protocol design of the Phase 2/3 adaptive clinical studies for both Lupus and CIDP.

Dr Goudreau obtained his PhD in Chemistry at the Université of Montréal as a NSERC fellow before moving to Switzerland to conduct postdoctoral studies at the ETH Zürich as an FRQNT fellow.

At this time, Dr Sanjeev Pandya, has informed the Board that he wishes to step down from his Non-Executive Director position, in order to pursue a number of other external opportunities.

All Board changes take place with immediate effect.

Commenting on the Board changes, Tim McCarthy, Chief Executive Officer said:

"I am delighted to welcome Laurence to the Board. His deep centred experience of late-stage drug development, together with his international business development expertise, will perfectly complement with and support the executive management team and together will ensure that we have the essential skills and knowledge required for the next stage of ImmuPharma's evolution.

I am also extremely pleased to welcome Sébastien to the Board. Having now worked closely with Sébastien over the last 2 years and seen first-hand how he has added invaluable insight and clinical direction within our drug portfolio, his appointment will be an extremely positive addition to the Board.

We are now on a pivotal course for ImmuPharma. As a Board, we remain focused on bringing our two key late stage P140 clinical assets in Lupus and CIDP through their final clinical trials and to the market.

We also continue to concentrate on further commercial and partnering opportunities and with these new Board appointments believe this may be accelerated over the next period. "

[the imperialist] 07/8/2023 11:03

IMM back in play?

[nobbygnome] 23/6/2023 09:57

Yes it would be worth trading IMM about 6 months before the results are due but this is a barge pole stock at present. Unless they can pull another rabbit out of the hat, this is going nowhere. Yes there is the other indication but their reputation for non delivery goes before them….

[colsmith] 23/6/2023 09:24

Problem is Nobby we just don't know if all three would fail or pass, its an element of luck (on a 1 shot), which is why Supers comment is so practical - there are so many variables as you obviously know. Supers last bit says it all.

I guess on Covid there is now massive info on effects - good and bad, unfortunately the bad only really comes out with real world use, just as it did with Thalidomide (Abstract from link below is interesting in this context). On news - there should be more this year on test and if the test starts some bits in 2024 on progress and maybe the final result, which is why its a good trade unless those in the market have other intentions?

You accept there is a chance the trial will be successful so I guess you agree there is reason to be positive and see trading the churn as a realistic policy!

The problem for IMM is that its a small guy (even with Avion), a big Pharma with P140 would have had more clout with Regulators and if the 1st trial had been done by a big Pharma I suggest things would be quite different on progress. Maybe IMM should have done a deal with a big Pharma, unless of course there is something in the agreement with CNRS to stop that.

Over and out but it seems this is one to watch - corporate action or share price trading opportunities?

From Supers
"and even then one would have to ask was it the increased dosing, or the narrower selection of patients, or something else entirely...?"

[nobbygnome] 22/6/2023 15:30

We won’t find out for at least 3 years so that isn’t the reason it’s going down now. More probable it’s just there won’t be any news for a while now

[purple11] 22/6/2023 15:25

2.55p on the bid now. collapsing

does the market actually know?

[purple11] 22/6/2023 15:19

so whats the market chances off this coming off?

THAT is how its being priced right now

the markets saying it could be a negative

[nobbygnome] 22/6/2023 13:40

It wasn’t even close to significance so it would have failed 3 out of 3! For the record I think it has a chance this time but of course it depends on what dosing regime they have chosen as it needs to be much higher…

[purple11] 22/6/2023 13:33

markets starting to price up a negative

will drop another 70%if it is

[colsmith] 22/6/2023 12:41

Question is guys - if the 1st P3 had been carried out three times would the result be:

- 3 fail, or 1 pass, or 2 pass, or 3 pass? Maybe the issue highlighted here is that the testing regime the industry uses is: - lucky to pass and the stuff isn't much good (or worse), or unlucky to fail and the stuff works.

IMO the useful action from the original P3 would be to start a use on market, could even be a Covid like emergency use, to get a so called real world result. After all it seems the stuff has, at the dosage level used, no or very little negative effect. Industry was very keen to get a real world Covid result! So regulators seem to have some interesting approval for market use!

The risk reward currently for the P3 test seems a good bet which is why trading until result would seem a good policy.

Supper's comment is perhaps the most practical on:

"First you aren't yet proven right - it will take a successful trial to be able to say that, and even then one would have to ask was it the increased dosing, or the narrower selection of patients, or something else entirely...?

[lord loads of lolly] 22/6/2023 11:03

Yes. By "worked", he meant it didn't kill anyone!

[nobbygnome] 22/6/2023 09:33

Plus the statement in an interview after the failed phase III that the drug ‘worked’ was unforgivable! McCarthy has a lot to answer for….

[lord loads of lolly] 22/6/2023 09:26

supernumerary - McCarthy has frequently misled investors in presentations & interviews. Remember the time he told us they could plough on, regardless of the FDA outcome? Only to find the FDA gave them comprehensive guidance (which it would have been commercial suicide to ignore, as any trial was sure to fail, short of following the guidance). So now - belatedly - they are. And you STILL respect him?!

[bumpa33] 22/6/2023 08:52

Nobby - clinical trials are a graveyard for wannabe drug solutions period ffs 🤦‍a94;️

[supernumerary] 21/6/2023 20:40

Oh dear Nobby, I would have thought you of all people would have known that pride is one of the seven deadly sins, and act accordingly?

First you aren't yet proven right - it will take a successful trial to be able to say that, and even then one would have to ask was it the increased dosing, or the narrower selection of patients, or something else entirely...?

And second, your constant denigration of McCarthy is, as I've already pointed out, utterly misplaced. He has, almost singlehandedly, kept this company alive: if anybody is to blame for the failed trials, it's the scientists, not him. I've no love for the guy but at least he's done his job, they haven't.

[colsmith] 21/6/2023 16:28

There is a reason for keeping price low, if that is what is going on, as another possibility from my 38543 - stimulate corporate action of some kind, such as some entity is interested in buying for what at £8Mcap is in relative terms small; one could see a large Pharma could buy for peanuts on the basis it passes, but if it doesn't its only £8M - probably a good bet?

PS - Lords "until something comes along that works" but it seems works only in statistical terms as the precise action of many/most all drugs is only known through dark glasses - the body is amazing complex system! In that sense it seems the test are usually one shot at P3 in that it could pass or fail; perhaps it should be the best of 3 P3's running concurrently - costly though; 2 out of 3 or ideally 3 out of 3 but 2 passes adequate.

[nobbygnome] 21/6/2023 13:53

Just for old time sake, here is the relevant post from 4th September 2017….

[lord loads of lolly] 21/6/2023 13:25

nobbygnome - couldn't you say that about any disease though? Littered with failed drug trials until something eventually comes along that works. Drugs generally cost a fortune because research & trials are so expensive & fallout rates so high. BTW, I've just posted on IMM's LSE board, where it was asked how anyone could know higher dosages would be required. Referred them to your multiple posts of many moons ago!

[nobbygnome] 21/6/2023 12:45

Well Bumpa if you look at the overall stats for clinical trials in lupus, you would find it is a graveyard for drugs. Add in that Lupuzor has failed before spectacularly, then the chances of success are already small…..

[bumpa33] 21/6/2023 11:16

Maybe they’ve learnt from their mistakes Nobby.

Otherwise you better give both IMM and Avion a call and tell ‘em not to bother with it!

[nobbygnome] 21/6/2023 10:58

Incidentally I don’t disagree that the price could well rise ahead of the results in late 2026/early 2027. However there is a lot of water to flow under the bridge before then…..and you would be very brave to hold for the actual results